Sales less than 2m below ABGSCe 30m EBITDA better than expected (SEK 0m vs.
Redeye states Acconeer’s net sales came in below expectations, driven by a postponement of a prepaid...
Redeye's provides its initial take on Genovis' year-end report which came in softer than we had esti...
Sales SEK 42m and EBIT SEK -3.7m (vs. ABGSCe 36m and -2.
Redeye comments on SHH´s fourth quarter. SSH posted a growth of 23% Y/Y, and EBITDA margin of 25%.
Minor estimate changes Potential start of variable revenue acceleration EV/ARR 2x, '25e EV/EBITDA ~8...
Redeye makes positive revisions to its financial projections and fair value range following Stille's...
Redeye updates on Invisio following its strong Q4-results and a continued positive outlook for 2025E...
Redeye comments on Alligator Bioscience's Q4 report and the rights issue, which was subscribed to 54...
Atria's Q4 fell short of expectations, but we believe it has reached a sustainably higher margin lev...
Redeye comments on Lytix Biopharma's Q4 report. During the quarter, Verrica reported further progres...
Redeye provides its comment on Mendus’ Q4 2024 report.
CapMan's Q4 was solid across the board, with both Management company business fee income and adjuste...
Q4: Sales in line, but EBIT beat on strong GM We slightly cut our sales estimate, but raise adj.
Redeye returns following IRLAB's Q4 report and recent news in the company.
